KURA Share Price Performance
US$8.65
1.00 (13.07%)
73.8% undervalued intrinsic discount
US$33.00
Fair Value
Price US$8.65
AnalystConsensusTarget US$33.00
AnalystHighTarget US$62.96
AnalystLowTarget US$16.00
Fair ValueUS$33.00
Share Pricen/a
Kura Oncology, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
KURA Community Narratives
AN
Fair Value US$33 73.8% undervalued intrinsic discount
Upcoming FDA Approval Will Open New Oncology Avenues
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value US$62.96 86.3% undervalued intrinsic discount
Aging Populations And Precision Medicine Will Widen Oncology Frontiers
1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$16 45.9% undervalued intrinsic discount
Menin Inhibition Headwinds Will Challenge Oncology Outlook Yet Long-Term Prospects Remain Intact
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Populations And Precision Medicine Will Widen Oncology Frontiers
Key Takeaways Ziftomenib's potential best-in-class profile and streamlined trial strategy could drive rapid adoption and transform revenue and margin growth in AML. Expanding into solid tumors and chronic diseases diversifies revenue opportunities and positions Kura as a platform company with strong long-term growth prospects.Read more
50
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$62.96
86.3% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
140.95% p.a.
Profit Margin
22.61%
Future PE
20.67x
Price in 2029
US$76.99
Upcoming FDA Approval Will Open New Oncology Avenues
Key Takeaways Anticipated drug approvals and a diverse pipeline in high-need oncology segments set the stage for accelerated revenue growth and market expansion. Strategic partnerships and industry trends support strong financial positioning, reduced risk, and sustainable long-term earnings potential.Read more
209
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
US$33
73.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
53.03% p.a.
Profit Margin
16.24%
Future PE
70.89x
Price in 2029
US$48.57
Menin Inhibition Headwinds Will Challenge Oncology Outlook Yet Long-Term Prospects Remain Intact
Catalysts About Kura Oncology Kura Oncology is a clinical stage biopharmaceutical company developing targeted therapies in precision oncology, with lead programs in menin inhibition for AML and farnesyl transferase inhibition for solid tumors. What are the underlying business or industry changes driving this perspective?Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$16
45.9% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
-10.96% p.a.
Profit Margin
16.03%
Future PE
177.89x
Price in 2028
US$19.23
Trending Discussion
Recently Updated Narratives
AN
KURA: FDA Approval And 2026 Guidance Will Reframe Long Term Prospects
Fair Value: US$62.96 86.3% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KURA: FDA Approval And Launch Execution Will Drive Future Upside
Fair Value: US$33 73.8% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Menin Inhibition Headwinds Will Challenge Oncology Outlook Yet Long-Term Prospects Remain Intact
Fair Value: US$16 45.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kura Oncology, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Mar 05, 2026
- -2.49
- -115.63%
- -208.48%
- 4.0%
About KURA
- Founded
- n/a
- Employees
- 192
- CEO
- WebsiteView website
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
